Skip to main content
Premium Trial:

Request an Annual Quote

Linkage Biosciences Raises $2M in Series B Round

Premium

Linkage Biosciences said this week that it has closed a Series B financing round worth $2 million.

Linkage markets the LinkSeq HLA product line, which uses a proprietary software and chemistry platform in conjunction with real-time PCR instrumentation for HLA typing. According to the company, LinkSeq is an end-point PCR process that uses allele-specific amplification combined with SYBR Green to detect PCR products on the instrument using melt-curve analysis.

Fisher Capital and Greenhouse Capital Partners led the Series B round, which follows $2 million in Series A financing that the company raised in 2009 and $1 million in venture financing from Greenhouse Capital in 2007.

Linkage said it will use the funds to expand its manufacturing capabilities, complete regulatory requirements in the US and Europe, and accelerate the development of additional molecular tests.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.